OpenAlex
PricingAboutJobs
Log inGet started
Work

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

HTML PDF

Year: 2015
Type: review
Source: Journal of the American College of Cardiology
DOI: 10.1016/j.jacc.2015.05.001
Authors: Robert P. Giugliano, Marc S. Sabatine
Institutions: Brigham and Women's Hospital, Harvard University
Language: English

Topic: Lipoproteins and Cardiovascular Health
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: PCSK9 inhibitors, PCSK9, LDL cholesterol lowering, LDL receptor degradation, PCSK9 monoclonal antibodies, cardiovascular outcomes, coronary artery disease, drug approval
SDG: Good health and well-being

Open Access status: bronze

Funders: Abbott Laboratories, Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Intarcia Therapeutics, Quest Diagnostics, MyoKardia, Daiichi-Sankyo, Eisai
OpenAlex ID: W569183658
FWCI: 5.724
Cites: 73
Cited by: 215
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security